Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan.
Genkiplaza Medical Center for Health Care, Tokyo, Japan.
J Clin Hypertens (Greenwich). 2021 Mar;23(3):687-691. doi: 10.1111/jch.14199. Epub 2021 Jan 26.
We tested our hypothesis that, in hypertensive patients with higher nocturnal home systolic blood pressure (HSBP) at baseline, a valsartan/cilnidipine (80/10 mg) combination would reduce nocturnal HSBP more markedly than a valsartan/hydrochlorothiazide (80/12.5 mg) combination. Patients measured their nocturnal HSBP over three nights prior to study randomization and at the end of treatment. Sixty-three and 66 patients comprised the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups; their respective baseline nocturnal HSBP values were 124.3 ± 15.6 and 125.8 ± 15.2 mm Hg (P = .597). Nocturnal HSBPs were significantly reduced from baseline in both groups. Although the valsartan/hydrochlorothiazide group exhibited a significantly greater reduction in nocturnal HSBP compared to the valsartan/cilnidipine group (-5.0 vs. -10.0 mm Hg, P = .035), interaction between the treatment groups and the baseline nocturnal HSBP levels for the changes in nocturnal HSBP after the treatment periods was significant (P = .047). The BP-lowering effect of valsartan/cilnidipine was more dependent on baseline nocturnal HSBP than that of valsartan/hydrochlorothiazide.
我们检验了这样一个假设,即在基线夜间家庭收缩压(HSBP)较高的高血压患者中,缬沙坦/西尼地平(80/10mg)联合用药比缬沙坦/氢氯噻嗪(80/12.5mg)联合用药更能显著降低夜间 HSBP。患者在研究随机分组前和治疗结束时连续三个晚上测量夜间 HSBP。63 名和 66 名患者分别入组缬沙坦/西尼地平组和缬沙坦/氢氯噻嗪组;他们各自的基线夜间 HSBP 值分别为 124.3±15.6 和 125.8±15.2mmHg(P=0.597)。两组夜间 HSBP 均较基线显著降低。尽管与缬沙坦/西尼地平组相比,缬沙坦/氢氯噻嗪组夜间 HSBP 的降低更为显著(-5.0 与-10.0mmHg,P=0.035),但治疗组间以及治疗后夜间 HSBP 变化与基线夜间 HSBP 水平之间的交互作用具有统计学意义(P=0.047)。缬沙坦/西尼地平的降压效果对基线夜间 HSBP 的依赖性强于缬沙坦/氢氯噻嗪。